Kinfo
Oric Pharmaceuticals, Inc. logo

Oric Pharmaceuticals, Inc.

ORICNASDAQHealthcare·US · USD
$8.82
+0.33 (+3.89%)
Prices as of November 6, 2026 · market closed

Price

Key statistics

Valuation
Market cap914.22M USD
Enterprise value709.35M USD
Trailing P/E-6.00
Forward P/E-5.03
PEG ratio0.31
Price / sales0.00
Price / book2.31
Profitability
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on assets-25.97%
Return on equity-39.80%
Income (TTM)
Revenue0.00 USD
Gross profit0.00 USD
EBITDA-155.00M USD
Net income-140.35M USD
Diluted EPS-$1.32
Rev. growth (YoY)0.00%
Balance sheet
Total cash264.76M USD
Total debt6.00M USD
Debt / equity1.57
Current ratio13.19
Book value / share$3.68
Cash flow (TTM)
Operating cash flow-111.64M USD
Levered free cash flow-68.83M USD
Shares & price
Shares outstanding103.64M
Float88.69M
Held by institutions122.63%
Beta1.21
50-day MA$12.19
200-day MA$11.10
52-week high$14.68
52-week low$7.23
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-08-03-0.36-0.38−5.56%2026-07-233.323.52+6.02%2026-05-04-0.32-0.34−6.25%2026-02-23-0.37-0.30+18.92%2025-11-13-0.40-0.33+17.50%
About Oric Pharmaceuticals, Inc.

Oric Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapies that address resistance to treatment. The company’s research pipeline centers on precision oncology, hormone-dependent cancers, and key tumor dependencies, with current programs designed to target mechanisms that limit the effectiveness of existing cancer medicines. Its product candidates include therapies in clinical development for genetically defined cancers and prostate cancer, along with additional discovery-stage oncology programs. Oric Pharmaceuticals operates as a single business segment and concentrates its efforts on advancing research, clinical development, and translational science for cancer treatment. The company is headquartered in South San Francisco, California, with additional operations supporting its development work in the United States. Its role in the market is to contribute experimental oncology candidates to the broader pipeline of targeted cancer therapeutics.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Jacob M. Chacko M.B.A., M.D.
Employees
111
Headquarters
South San Francisco, CA, United States

Frequently asked questions about Oric Pharmaceuticals, Inc.